Sarepta Therapeutics, Inc.
Oligonucleotide analogues targeting human LMNA
Last updated:
Abstract:
Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
Status:
Grant
Type:
Utility
Filling date:
17 Apr 2019
Issue date:
27 Jul 2021